This article highlights the recent developments at Unlearn, a biotech AI startup that secured $15 million in funding and added OpenAI CTO Greg Brockman to its board. The move is expected to accelerate the company’s growth and strengthen its position in the biotech industry.
Unlearn. AI has received $15 million to develop alliances and hasten regulatory approval. The business has constructed a machine learning platform that produces “digital twin” profiles of patients in clinical trials.
According to the firm, the investment from Radical Ventures and Wittington Ventures valued the venture at $265 million.
Mira Murati, the chief technical officer of Microsoft-backed OpenAI, has joined the company’s board of directors.
While generative AI is commonly used to generate material such as writing, graphics, and even computer code, Unlearn utilises it to create digital twins to accelerate clinical drug trials using neural networks.
If effective, Unlearn’s software might save medication companies money by reducing the number of people needed for clinical studies by substituting those who get a placebo.
Unlearn obtained the funds after receiving authorization from the European Medicines Agency (EMA) in September to use its AI-driven strategy for performing smaller and faster clinical trials, as well as striking multiple multi-million dollar partnerships with pharmaceutical giants such as Merck.
Unlearn, situated in San Francisco, focuses on a relatively new use of generative AI. The technique, in which AI learns how to execute actions based on historical data, has gained popularity through applications such as OpenAI’s viral chatbot ChatGPT.
Unlearn’s technology computes a twin for each patient in a clinical trial using patient data from research studies and populates the control arm of the study with these twins.
With an emphasis on Phase III clinical studies, Unlearn CEO Charles Fisher stated that obtaining licences from authorities such as the US Food and Drug Administration is vital to commercialising the technology to global drugmakers.
Unlearn has received $85 million in funding from investors such as Insight Partners, 8VC, and Mubadala Ventures.
